

ATTN: APPLICATION BRANCH

**THIS IS A RESPONSE TO A  
NOTICE TO COMPLY WITH REQUIREMENTS FOR  
PATENT APPLICATIONS CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

Re: Inventor: Naoto TONOUCHI, et al.  
Serial No: 10/763,249  
Filed: January 26, 2004  
For: PEPTIDE-FORMING ENZYME GENE, PEPTIDE-FORMING  
ENZYME, AND PEPTIDE PRODUCING METHOD

SIR:

Attached hereto for filing are the following papers:

Return Copy - Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or  
Amino Acid Sequence Disclosures

Preliminary Amendment and Statement w/attached Sequence Listing and Computer Readable Form (CRF)

Submission of Supplemental Application Data Sheet

Supplemental Application Data Sheet (3 pp.)

IDS/Related/List of Related Cases

Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure  
w/Partial Translation (FERM BP-8101)

Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure  
w/Partial Translation (FERM BP-8123)

International Preliminary Examination Report

Our check in the amount of \$0.00 is attached covering any required fees. In the event that any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 CFR 1.136 for the necessary extension of time. A duplicate of this sheet is enclosed.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

Docket No. 247264US0CONT

Customer Number


**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Vincent K. Shier, Ph.D.

Registration No. 50,552

DOCKET NO.: 247264US0CONT/sfb



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

Naoto TONOUCHI, et al.

GROUP: 1642

SERIAL NO: 10/763,249

FILED: January 26, 2004

EXAMINER:

FOR: PEPTIDE-FORMING ENZYME GENE, PEPTIDE-FORMING ENZYME, AND  
PEPTIDE PRODUCING METHOD

**SUBMISSION OF SUPPLEMENTAL APPLICATION DATA SHEET**

Office of Initial Patent Examination  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant(s) submit herewith a Supplemental Application Data Sheet for the above-identified application for the purpose of correcting the Applicants' city of residence.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

---

Vincent K. Shier, Ph.D.  
Registration No. 50,552

Customer Number

**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 06/04)



UNITED STATES PATENT AND TRADEMARK OFFICE

Sequence / ifw

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/763,249	01/26/2004	Naoto Tonouchi	247264US0CONT

CONFIRMATION NO. 8012

22850  
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.  
1940 DUKE STREET  
ALEXANDRIA, VA 22314

## FORMALITIES LETTER



\*OC000000013492007\*

Date Mailed: 08/10/2004

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
Commissioner for Patents

P.O. Box 1450  
Alexandria VA 22313-1450



*A copy of this notice **MUST** be returned with the reply.*

---

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE